Dopamine Receptor Modulator

Desmethyl cariprazine (Standard) is the analytical standard of Desmethyl cariprazine (HY-100656). This product is intended for research and analytical applications. Desmethyl cariprazine is an active metabolite of Cariprazine. Cariprazine, an antipsychotic agent candidate, exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (0.49 nM) receptors, and moderate affinity for the 5-HT1A receptor (2.6 nM).

Cariprazine (Standard) is the analytical standard of Cariprazine. This product is intended for research and analytical applications. Cariprazine is a novel antipsychotic agent candidate that exhibits high affinity for the D₃ (K_i=0.085 nM) and D₂ (K_i=0.49 nM) receptors, and moderate affinity for the 5-HT_1A receptor (K_i=2.6 nM).

BP 897 hydrochloride (Standard) is the analytical standard of BP 897 (hydrochloride) (HY-106660). This product is intended for research and analytical applications. BP 897 hydrochloride is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 hydrochloride displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM).

SRI-45949 is an allosteric modulator of the HIV-DAT-Tat interaction. SRI-45949 has IC₅₀ values of 9.56 μM and 9.34 μM for [³H]DA uptake and [³H]WIN35,428 binding, respectively. SRI-45949 can be used in research related to HIV-associated neurocognitive disorders.

PAOPA (Standard) is the analytical standard of PAOPA (HY-103423). This product is intended for research and analytical applications. PAOPA, an analog of L-proline-l-leucine-glycine amide (PLG) peptide, is an allosteric modulator of Dopamine D2 Receptor. PAOPA can effectively reduce behavioral abnormalities in rodent models of schizophrenia. PAOPA increases the high affinity dopamine D2 receptor and promotes its binding to agonists.

Ordopidine hydrochloride is a modulator of dopamine receptor extracted from patent WO/2005/121087A1, compound example 2; exhibits an ED₅₀ of 68 μmol/kg on increase of DOPAC in the rat striatum.